Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial

Abstract Background As 40–60% of the patients with obsessive-compulsive disorder (OCD) do not adequately respond to the first-line treatment, finding an effective second-line treatment is required. Our aim was to assess the efficacy and safety of agomelatine (a selective melatonin receptor agonist a...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Marjan Shokrani, Sanaz Askari, Negin Eissazade, Seyed Vahid Shariat, Behnam Shariati, Masoomeh Yarahmadi, Mohammadreza Shalbafan
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2023-09-01
Edice:	BMC Psychiatry
Témata:	Agomelatine Obsessive-compulsive disorder Sertraline Selective serotonin reuptake inhibitors
On-line přístup:	https://doi.org/10.1186/s12888-023-05189-7
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!